McKesson and CD&R Announce $5.8B Agreement to Acquire Option Care Health
McKesson and Clayton, Dubilier & Rice announced a definitive agreement to acquire Option Care Health for $32.05 per share, representing approximately $5.8 billion in enterprise value. At closing, CD&R is slated to hold approximately 51% and McKesson approximately 49%, while Option Care is to remain a separate company under its own management.
The atomic development is the definitive acquisition agreement, not any related share-price movement. McKesson and Clayton, Dubilier & Rice explicitly announced an agreement to acquire Option Care Health at $32.05 per share and approximately $5.8 billion of enterprise value, making this a material, forward-looking change-of-control event correctly typed as merger_acquisition. Importance is high because this is a major announced M&A transaction, while surprise is moderated because a report the prior day said the parties were nearing an agreement and could reach one on October 6. Core-fact confidence is high, but the exact occurrence time is estimated from the earliest direct report because the provided context explicitly confirms the date but not the announcement time. OPCH and MCK are directly affected; INFU, UNH, CVS, BTSG, and ELV are approved because the context identifies clear home-infusion competitive channels. CAH and BAX are excluded because their relationship to this specific transaction is more indirect and insufficiently event-specific, and no symbol is provided for CD&R.
*CD&R, MCKESSON TO BUY OPTION CARE HEALTH FOR $32.05/SHR